Genmab A/S
GMAB21.975USD
+0.195+0.90%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.39BCap. mercado
0.41P/E TTM
Más Datos de Genmab A/S Compañía
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Información de la empresa
Símbolo de cotizaciónGMAB
Nombre de la empresaGenmab A/S
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoDr. Jan G.J. Van De Winkel, Ph.D.
Número de empleados2682
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
DirecciónCarl Jacobsens Vej 30
CiudadVALBY
Bolsa de valoresOMX Nordic Exchange Copenhagen A/S
PaísDenmark
Código postal2500
Teléfono4570202728
Sitio Webhttps://www.genmab.com/
Símbolo de cotizaciónGMAB
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoDr. Jan G.J. Van De Winkel, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
Accionistas
Accionistas
Proporción
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
4.27%
Investment Advisor
2.99%
Hedge Fund
2.45%
Research Firm
0.51%
Pension Fund
0.03%
Bank and Trust
0.02%
Venture Capital
0.01%
Other
89.73%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
498
64.99M
10.26%
-6.57M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
2023Q1
481
44.22M
6.78%
-6.32M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AllianceBernstein L.P.
14.73M
2.32%
-210.07K
-1.41%
Mar 31, 2025
Orbis Investment Management Ltd.
5.71M
0.9%
+2.90M
+102.83%
Mar 31, 2025
Citadel Advisors LLC
4.43M
0.7%
+1.33M
+43.16%
Mar 31, 2025
Two Sigma Investments, LP
3.87M
0.61%
+513.60K
+15.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.95M
0.47%
-433.32K
-12.82%
Mar 31, 2025
Harding Loevner LP
2.88M
0.45%
+637.43K
+28.41%
Mar 31, 2025
Renaissance Technologies LLC
2.26M
0.36%
+336.20K
+17.45%
Mar 31, 2025
Marshall Wace LLP
2.18M
0.34%
+1.06M
+94.38%
Mar 31, 2025
Brandywine Global Investment Management, LLC
1.72M
0.27%
+97.63K
+6.03%
Mar 31, 2025
First Trust Advisors L.P.
1.71M
0.27%
+65.52K
+3.98%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Tema Oncology ETF
3.66%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
WisdomTree BioRevolution Fund
0.99%
iShares Biotechnology ETF
0.87%
First Trust NASDAQ BuyWrite Income ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
Avantis International Equity ETF
0.07%
ActivePassive International Equity ETF
0.07%
Avantis International Large Cap Value ETF
0.05%
Ver más
Tema Oncology ETF
Proporción3.66%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.45%
WisdomTree BioRevolution Fund
Proporción0.99%
iShares Biotechnology ETF
Proporción0.87%
First Trust NASDAQ BuyWrite Income ETF
Proporción0.2%
ProShares Ultra Nasdaq Biotechnology
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.1%
Avantis International Equity ETF
Proporción0.07%
ActivePassive International Equity ETF
Proporción0.07%
Avantis International Large Cap Value ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
